Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

HBM Healthcare Investments AG / Key word (s): Annual Results HBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial year 01-Apr-2025 / 17:49 CET/CEST ...

The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...

In a bid to pursue growing sales, Sanofi doubled down on investing in immunology with the $600 million upfront buyout of Dren Bio’s clinical stage bispecific antibody. The antibody has been evaluated ...

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

Sanofi signs $1.9bn deal to buy Dren Bio autoimmune drug UK is becoming an 'outlier' for pharma, hitting investment Sofinnova closes new fund and backs a trio of new biotechs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.